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Introduction
Leptin is a protein encoded by the ob gene and appears
to play an important role in energy expenditure, neu-
roendocrine-reproductive systems, and immune response
[1,2]. Its concentration is related to the mass of adi-
pose tissue [3]. There are several factors influencing
circulating leptin levels. Gender and menapouse related
differences in leptin levels have been reported [4]. The
production of leptin is under a complex hormonal con-
trol [5]. Some studies have found that estrogens both
in vivo [6,7] and in vitro [7] increase serum leptin, whereas
androgens may show the opposite effect [8]. But some
recent studies reported that hypogonadism does not
influence serum leptin levels in women if body fat mass
is unchanged [9,10].
Uterine leiomyomas are the most common pelvic
tumors leading to hysterectomy [11]. Dietary fat intake,
high body mass index (BMI), estrogen, and progesterone
are well-known risk factors for myoma uteri [12,13].
These risk factors may also affect serum leptin levels [14].
Chan et al [15] reported decreased serum leptin levels
in women with myoma uteri, and a recent study by
Markowska et al [16] reported expression of the leptin
gene both in myomas and in the surrounding myome-
trium but not in the myometrium of healthy women. In
this study, effect of leptin on myoma uteri formation is
examined.
Materials and Methods
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SUMMARY
Objective: The purpose of this study was to examine the influence of leptin in women with uterine myoma.
Materials and Methods: In this study, 38 women with myoma uteri and 30 normal women who applied to the
Dr Zekai Tahir Burak Woman Health Research and Education Hospital’s gynecology clinic were enrolled.
Uterine leiomyomas were proved by pathology postoperatively. In all subjects, FSH, LH, E2, prolactin, hemo-
globin, hematocrit, blood urea nitrogen, creatinine, fasting glucose, CA125, and leptin were examined, and body
mass index (BMI) was calculated. Data were analyzed by Student’s t test and Mann-Whitney U test.
Results: Although leptin level was higher in the myomatic women (5.73 ± 4.08 ng/mL) than in the normal
women, there was no statistically significant difference (p = 0.303). Also, no statistical difference in the ratios
of leptin/BMI was found in both groups. A significant correlation was found between high E2 level and myoma
uteri (p = 0.021). Hemoglobin levels were significantly lower in the myomatic women (p = 0.044). When we
compared the leptin levels according to BMI, leptin levels were higher in patients who had BMI > 30 (p = 0.02).
Conclusion: We did not find any significant difference in serum leptin levels between the two groups. But leptin
may have an indirect role in the pathogenesis of uterine leiomyoma. So further research is needed to reveal the
role of leptin in myoma uteri pathogenesis. [Taiwanese J Obstet Gynecol 2007;46(1):33–37]
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Health Research and Education Hospital’s gynecology
clinic were enrolled in this study. A written informed
consent was obtained from each women and the study
was approved by the Ethics Committee of our hospital.
Uterine leiomyomas were proved by pathology after
operation. No myoma uteri was detected in normal
women by ultrasonographic examination. Women
enrolled in this study were questioned carefully about
their medical history and women with hypertension,
chronic renal failure,diabetes mellitus, or chronic drug
usage were excluded.
Serum samples of myomatic women and control
group samples were collected in the proliferative phase
of menstrual cycle. All samples were stored at −20°C
until further analysis. In serum samples FSH, LH, E2,
prolactin, hemoglobin, hematocrit, blood urea nitrogen
(BUN), creatinine, fasting glucose, CA125, and leptin
were examined. In both groups, BMI was calculated.
Serum leptin levels were measured using the
BioSource Leptin Easia kit (BioSource Europe SA,
Nivelles, Belgium).
Statistical analysis was performed with SPSS version
11.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics
are presented as mean ± standard deviation. Intragroup
comparisons were performed using Student’s t test
and Mann-Whitney U test; p < 0.05 was considered
significant.
Results
The clinical characteristics and laboratory parameters
of myomatic women and control group are shown in
Table 1.
There was no significant difference between myoma-
tic and normal women with respect to age, gravidity,
parity, BMI, renal function tests, and blood glucose
levels. Hemoglobin levels, however, were significantly
lower (p = 0.044) in the myomatic women. The CA125,
E2, FSH, LH, and prolactin levels for both groups are
shown in Table 2.
There was no statistical difference in FSH, LH, 
CA125, and prolactin between the two groups. However,
E2 level was significantly higher in the myomatic group
(p = 0.021).
Serum leptin levels in the myomatic group was
5.73 ± 4.08 ng/mL, while it was 4.75 ± 3.53 ng/mL in
the control group. Although leptin level was higher in the
myomatic group, there was no significant difference
(p = 0.303). There was also no statistically significant
difference in the ratios of leptin/BMI between the two
groups (Table 3).
Serum leptin levels in the myomatic group were
evaluated according to the size of myoma uteri. Leptin
levels in 21 patients who had myoma uteri < 5 cm were
6.35 ± 4.78 ng/mL. In 10 patients who had myoma
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Table 1. Clinical characteristics and laboratory parameters*
Myomatic group (n = 38) Control group (n = 30) p
Age (yr) 45.76 ± 4.12 44.13 ± 3.40 0.085
Gravidity 4.66 ± 1.90 4.60 ± 2.16 0.907
Parity 3.21 ± 1.26 3.10 ± 1.09 0.704
BMI (kg/m2) 29.14 ± 3.93 27.65 ± 4.06 0.132
Hb (g/dL) 11.41 ± 2.15 12.46 ± 1.99 0.044
Hct (%) 35.83 ± 4.52 37.89 ± 4.64 0.069
BUN (mg/dL) 27.21 ± 6.45 26.67 ± 7.56 0.751
Glucose (mg/dL) 100.89 ± 19.86 94.17 ± 10.87 0.081
Creatinine (mg/dL)† 0.70 0.70 0.415
*Data are presented as mean ± standard deviation (Student’s t test); †median value (Mann-Whitney U test). BMI = body mass index; BUN = blood urea nitrogen.
Table 2. Serum levels of CA125 and hormones
Myomatic group (n = 38) Control group (n = 30) p
CA125 (IU/mL)* 20.34 ± 9.93 17.36 ± 5.97 0.130
E2 (pg/mL)* 116.6 ± 89.16 77.23 ± 45.11 0.021
FSH (mIU/mL)† 9.16 ± 2.07 7.67 ± 1.97 0.309
LH (mIU/mL)† 5.02 ± 2.32 4.08 ± 2.53 0.338
PRL (ng/mL)† 16.05 ± 1.52 14.91 ± 1.79 0.543
*Mean ± standard deviation; †geometric mean ± standard deviation. BMI = body mass index.
uteri > 5 cm, leptin levels were 5.29 ± 2.81 ng/mL. In
seven patients in whom myoma uteri were > 5 cm and
< 5 cm in size, leptin level was 4.49 ± 3.38 ng/mL. There
was no significant difference among the three groups
regarding leptin levels. There was a trend of leptin levels
decreasing when the size of myoma uteri was increasing.
Leptin levels according to BMI were also compared.
The whole study group was divided into the two groups:
BMI > 30 and < 30. Forty-five patients had BMI < 30 and
23 patients had BMI > 30. There was statistically signifi-
cant difference between the two groups (p = 0.02)
(Table 4). Leptin levels were higher in patients who had
BMI > 30.
Hemoglobin levels in the myomatic group were lower
than in the control group. But there was no significant
difference when hemoglobin and leptin levels were
compared (p = 0.372) (Table 5).
Discussion
Uterine leiomyomas are the most common pelvic tumors
leading to hysterectomy [11]. There are many known
risk factors for myoma uteri such as dietary fat intake,
high BMI, estrogen, and progesterone [12,13].
Leptin is a protein encoded by the ob gene and
appears to play an important role in reproductive system
[1,2]. So risk factors for myoma uteri may be involved
in the regulation of leptin [14]. Chan et al reported lower
serum leptin levels in the myomatic women than the
normal women [15]. Recently, Markowska et al reported
expression of the leptin gene both in myomas and in
the surrounding myometrium but not in the myometrium
of healthy women [16]. In our study, although leptin
levels were higher in the myomatic group than in the
control group, there was no significant difference. Some
factors such as BMI, blood glucose levels, renal function
tests, and age, which can affect serum leptin levels, were
similar between our two study groups, so that does not
explain the situation.
Nowicki et al also had similar results with our report
indicating that 12 weeks of goserelin treatment in the
myomatic group caused a significant regression of
myoma but no change in plasma leptin level even after
correction for fat mass [9]. BMI and body fat mass were
the major determinants of plasma leptin, especially total
body fat mass [6]. So direct measurement of body 
fat with DEXA would be better. Higher leptin levels in
patients with high BMI in our study is consistent with
other reports [4,6].
The role of sex steroids in the leptin production has
been investigated. Both estrogen and androgen levels
have been found to correlate with leptin levels [17,18].
Shimizu et al [19] and Cella et al [20] reported corre-
lation between leptin and estradiol levels throughout
the menstrual cycle, while Paolisso et al [21] indicated
correlation with plasma progesteron, but not with estra-
diol. Most human studies that show a link between
leptin and estradiol are cross-sectional [17] or obser-
vational [22]. In animal experiments in ovariectomized
mice, the administration of estradiol did not influence
circulating leptin levels, and ovariectomy did not change
leptin secretion if it was not accompanied by changes
in body fat mass [23]. But in recent reports, there is
conflicting data about leptin levels after ovariectomy
in rats; Chu et al [24] reported a decline in plasma leptin
levels, while Pinilla et al [25] indicated an increase in
plasma leptin levels after ovariectomy in rats.
Serum leptin concentrations throughout the men-
strual cycle remain controversial. Some authors reported
an increase in the luteal phase [19,26,27], while others
reported no difference between follicular and luteal
phases [28].
Gorden and Gavrilova reported that leptin therapy
restores gonadotrophin secretion and menstrual cycle
[29]. In our study, some patients from both groups had
menstrual dysfunction. This may explain why we did
not find a significant difference.
Immunologic factors in myoma uteri etiology have
been investigated for years. Malyshkina et al [30] found
impairment in differentiation of lymphocytes in rapidly
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Table 3. Leptin levels and the ratio of leptin/body mass
index (BMI)
Myomatic Control p
group (n = 38) group (n = 30)
Leptin (ng/mL) 5.73 ± 4.08 4.75 ± 3.53 0.303
Leptin/BMI 0.19 ± 0.12 0.17 ± 0.13 0.509
Table 4. Leptin levels according to body mass index (BMI)
n Leptin level (ng/mL)
BMI > 30 45 4.27 ± 3.15
BMI < 30 23 7.29 ± 4.38
Table 5. Leptin levels according to the hemoglobin levels
of the study group
n Leptin level (ng/mL)
Hb < 11 g/dL 20 5.95 ± 4.03
Hb > 11 g/dL 48 5.02 ± 3.79
growing large myomas. Immunoregulatory properties of
leptin on CD4+ T cells and immune system reconstitu-
tion by leptin therapy in leptin deficient patients have
been reported [31]. So leptin administration may take
place in myoma uteri treatment in the future.
In the literature, the leptin effect on myoma uteri
formation is still uncertain. This may be due to many
factors affecting leptin levels. In further research, all
known factors affecting leptin levels, such as menstrual
phase, age, BMI, total body fat, dietary, and exercise
habits, must be matched very carefully with the con-
trol group with a large sample size. A study containing
these strict criteria is still absent in the literature.
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